Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,119 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dyslipidemia Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

NCT00794677
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ezetimibe, placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

NCT01372358
View directory record Official record
Conditions
Fed
Interventions
CIPRO®XR
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 4 Interventional

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

NCT00185107
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Colesevelam Hydrochloride, Ezetimibe, Simvastatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2007 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Change in Diet May Decrease the Negative Consequences of Chronic Sleep Deprivation

NCT00123214
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Controlled Dietary Intervention
Drug
Lead sponsor
St. Vincent's Medical Center
Other
Eligibility
25 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2006 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

NCT00296400
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
23
States / cities
Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 21, 2026, 9:42 AM EDT
Not listed Phase 3 Interventional

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
AKR-963
Drug
Lead sponsor
Trygg Pharma, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 21, 2026, 9:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

NCT01242319
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Disease, Primary Health Care, Management, Risk
Interventions
HeartAge intervention
Behavioral
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
18 Years to 80 Years
Enrollment
5,218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Dietary Fiber on Blood Lipids in Men and Women

NCT02835872
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
dietary fiber
Other
Lead sponsor
Tate & Lyle
Industry
Eligibility
21 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients

NCT01811472
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
LCQ908, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional

Pharmacy Interventions to Improve Chronic Disease Medication Refill

NCT00469365
View directory record Official record
Conditions
Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions
pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Not listed
Enrollment
3,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2008 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Enlicitide Chloride (MK-0616) in Healthy Participants and Participants Taking Statins (MK-0616-012)

NCT06655311
View directory record Official record
Conditions
Healthy, Hypercholesterolemia
Interventions
Enlicitide Chloride, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Octacosanol During Taekwondo Training

NCT03557476
View directory record Official record
Conditions
Oxidative Stress, Dyslipidemias
Interventions
Octacosanol, Placebo
Dietary Supplement
Lead sponsor
Kosin University
Other
Eligibility
17 Years to 19 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

NCT03330548
View directory record Official record
Conditions
Hyperlipidemias, Overweight and Obesity, Diabetes
Interventions
TeleMOVE!, Culinary Rx
Behavioral
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
18 Years to 89 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 2 Interventional

The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects

NCT01893515
View directory record Official record
Conditions
Dyslipidemia
Interventions
PRC-4016, Placebo
Drug
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years to 79 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
39
States / cities
Huntsville, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 21, 2026, 9:42 AM EDT
Not listed Phase 1Phase 2 Interventional

Standard Process 21 Day Purification Program Project

NCT00724217
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Standard Process 21 Day Purification Program (SPPP)
Other
Lead sponsor
Logan College of Chiropractic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

NCT00797407
View directory record Official record
Conditions
Hypercholesterolemia, Aches, Cramps, Weakness
Interventions
Creatine
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Wooster, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2008 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of a Holistic Health Program for United Methodist Clergy

NCT01564719
View directory record Official record
Conditions
Obesity, Depression, Diabetes, Hypertension, Hypercholesterolemia
Interventions
Holistic health
Behavioral
Lead sponsor
Duke Clergy Health Initiative
Other
Eligibility
18 Years and older
Enrollment
1,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)

NCT05934292
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Enlicitide Decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Hallandale, Florida • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 21, 2026, 9:42 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

NCT00927459
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PRO-040201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2010 · Synced Oct 21, 2026, 9:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

NCT02959762
View directory record Official record
Conditions
Obesity, Insulin Resistance, Obesity in Diabetes, Nutritional and Metabolic Diseases, Hyperlipidemia, Hyperglycemia, Cardiovascular Diseases
Interventions
Placebo-Control, Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d), High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 21, 2026, 9:42 AM EDT
Completed Phase 4 Interventional

The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control

NCT00282659
View directory record Official record
Conditions
Coronary Artery Disease, Hypertension, Dyslipidemia, Diabetes
Interventions
magnesium L-lactate
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 21, 2026, 9:42 AM EDT